Mitogen-activated protein kinase kinase (also known as MAP2K) is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).
MAP2K is classified as
There are seven genes:
The activators of
p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways. [1 ]
Role in Melanoma [ edit ]
MEK is a member of the MAPK signaling cascade that is activated in melanoma.
When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced. [2 ]
See also [ edit ]
References [ edit ]
^ Dérijard B, et al. (1995). "Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms". Science 267 (5198): 682–5. doi: 10.1126/science.7839144. PMID 7839144.
^ Falchook, Gerald S, Karl D Lewis, Jeffrey R Infante, Michael S Gordon, Nicholas J Vogelzang, Douglas J DeMarini, and Leslie A Fecher, et al. 2012. "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial." The Lancet Oncology 13, no. 8: 782-789.
External links [ edit ]
MAP kinase activation
MAP kinase kinase kinase (MAP3K or MKKK)
MAP kinase kinase (MAP2K or MKK)
B trdu: iter ( nrpl/ grfl/ cytl/ horl), csrc ( lgic, enzr, gprc, igsr, intg, nrpr/ grfr/ cytr), itra ( adap, gbpr, mapk), calc, lipd; path ( hedp, wntp, tgfp+ mapp, notp, jakp, fsap, hipp, tlrp)